Stockreport

Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why [Yahoo! Finance]

Zentalis Pharmaceuticals, Inc. - common stock  (ZNTL) 
PDF The company is developing its lead product candidate, azenosertib, a potentially first-in-class WEE1 inhibitor, as a monotherapy and in combination with other therapies [Read more]